MAFA
VKTX icon

MJT & Associates Financial Advisory’s Viking Therapeutics VKTX Stock Holding History

MJT & Associates Financial Advisory’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-350
Closed -$9.2K – 477
2025
Q3 		$9.2K Hold
350
– – 0.01% 199
2025
Q2 		$9.28K Hold
350
– – 0.01% 216
2025
Q1 		$8.45K Buy
+350
New +$11.1K 0.01% 226

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MJT & Associates Financial Advisory's VKTX Position: Q4 2025 in Review

MJT & Associates Financial Advisory sold out of Viking Therapeutics (VKTX) in Q4 2025, closing a stake of 350 shares — an estimated $9.2K sold.

MJT & Associates Financial Advisory first reported a position in VKTX in Q1 2025 and held it in 3 quarters. The position peaked at $9.28K in Q2 2025. 424 funds tracked by Wall St. Rank hold VKTX as of Q4 2025.

  • MJT & Associates Financial Advisory reported no remaining Viking Therapeutics position as of Q4 2025 after selling out during the quarter.
  • MJT & Associates Financial Advisory sold 350 Viking Therapeutics shares in Q4 2025, an estimated $9.2K.
  • MJT & Associates Financial Advisory first reported a position in Viking Therapeutics in Q1 2025 and held it in 3 quarters.
  • MJT & Associates Financial Advisory's Viking Therapeutics position peaked at $9.28K in Q2 2025.
  • 424 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2025.

Based on MJT & Associates Financial Advisory's 13F filing for Q4 2025, filed 10 Feb 2026.